Stefan Sperl

Director de Operaciones en KIORA PHARMACEUTICALS, INC. .

Health Technology

Consumer Services

Perfil

Stefan Sperl was the founder of Panoptes Pharma GmbH, founded in 2013, holding the title of Chief Operating Officer.
Dr. Sperl is currently the Executive Vice President-CMC & Operations at Kiora Pharmaceuticals, Inc. Formerly, Project Manager at Nabriva Therapeutics GmbH.
Education includes a doctorate from Max Planck Institute of Biochemistry.

Cargos activos de Stefan Sperl

Empresas	Cargo	Inicio
KIORA PHARMACEUTICALS, INC.	Director de Operaciones	-

Todos los cargos activos de Stefan Sperl

Antiguos cargos conocidos de Stefan Sperl.

Empresas	Cargo	Fin
Nabriva Therapeutics GmbH Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Provides pharmaceutical research and development services	Corporate Officer/Principal	-
Panoptes Pharma GmbH Panoptes Pharma GmbH BiotechnologyHealth Technology Develops molecule drugs to treat eye diseases	Fundador	-

Ver el detalle de la experiencia de Stefan Sperl.

Formación de Stefan Sperl.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Stefan Sperl.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	4
Kiora Pharmaceuticals, Inc. Kiora Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for the treatment of ophthalmic diseases	Health Technology
Nabriva Therapeutics GmbH Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Provides pharmaceutical research and development services	Health Technology
Max Planck Institute of Biochemistry Max Planck Institute of Biochemistry Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Panoptes Pharma GmbH Panoptes Pharma GmbH BiotechnologyHealth Technology Develops molecule drugs to treat eye diseases	Health Technology